Aytu BioScience (AYTU) AI Stock Analysis

• Market Cap: $28.02M
• Dividend Yield: N/A
• Average Volume (3M): 314.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: -15.61%
• EPS Growth: -68.96%
• Country: US
• Employees: 102
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 10,188,208
• 10 Day Avg. Volume: 289,104
• 30 Day Avg. Volume: 314,725
• PEG Ratio: 0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -2.65
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 0.11
• Enterprise Value/Gross Profit: 0.16
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $9.33
• Price Target Upside: 239.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $3.00 ▲(9.09% Upside)

The score is held down primarily by weak financial performance (ongoing losses, negative cash flow, and TTM revenue contraction). Technicals are supportive with an uptrend, but overbought signals increase near-term risk. The earnings call adds some optimism around the EXXUA launch and cash position, while valuation remains challenged due to unprofitability.

Positive Factors

EXXUA Launch Progress

The timely launch of EXXUA, with strategic advancements, indicates potential for significant market impact, enhancing long-term growth prospects in the major depressive disorder treatment market.

Patent Extension for EXXUA

The patent extension for EXXUA strengthens Aytu's competitive position by securing exclusive rights, potentially leading to sustained revenue from this product line.

Strong Cash Position

A strong cash position provides financial flexibility to invest in growth opportunities and manage operational challenges, supporting long-term stability.

Negative Factors

Decline in Pediatric Portfolio Revenue

The decline in pediatric portfolio revenue highlights operational challenges and potential market share loss, impacting long-term revenue diversification.

Gross Margin Decline

A declining gross margin indicates rising costs or pricing pressures, which could erode profitability and affect long-term financial health.

Regulatory Concerns on Fluoride Products

Regulatory scrutiny on fluoride products could lead to increased compliance costs or restrictions, affecting future product lines and revenue streams.

Aytu BioScience Business Overview & Revenue Model

Company Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

How the Company Makes Money

Aytu BioScience generates revenue through the sale of its pharmaceutical products and diagnostic tests. The company has a diversified revenue model that includes direct sales of its proprietary products, as well as partnerships with other pharmaceutical companies for co-promotion and distribution. Key revenue streams are derived from product sales in the urology and pediatric markets, where Aytu has established a presence. Additionally, the company may benefit from licensing agreements, collaborations, and research grants that contribute to its financial performance. Strategic partnerships with healthcare providers and institutions also play a crucial role in expanding its market reach and enhancing sales.

Aytu BioScience Financial Statement Overview

Summary

Aytu BioScience faces significant financial challenges, with declining revenues and persistent losses impacting profitability. The company maintains a manageable debt level, but its negative return on equity and cash flow issues highlight the need for strategic improvements to enhance financial stability and growth prospects.

Income Statement

Aytu BioScience's income statement reveals challenges with profitability and revenue growth. The company has experienced a decline in revenue over the past year, with a negative revenue growth rate of -4.10%. Gross profit margin remains relatively strong at 69.04%, indicating efficient production, but the net profit margin is negative at -20.43%, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.10, suggesting manageable leverage. However, the return on equity is significantly negative at -71.51%, indicating poor returns for shareholders. The equity ratio stands at 15.27%, showing a reasonable proportion of equity financing relative to total assets.

Cash Flow

Cash flow analysis indicates a concerning decline in free cash flow growth at -62.28%. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is positive at 1.12, suggesting that free cash flow covers net losses, albeit with limited margin.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	63.70M	66.38M	65.18M	107.40M	96.67M	65.63M
Gross Profit	43.03M	45.83M	49.05M	66.63M	50.28M	29.20M
EBITDA	-5.47M	-4.67M	1.41M	-3.27M	-27.96M	-29.04M
Net Income	-13.07M	-13.56M	-15.84M	-17.05M	-108.78M	-58.29M
Balance Sheet
Total Assets	124.99M	124.18M	118.86M	137.84M	137.62M	265.67M
Cash, Cash Equivalents and Short-Term Investments	32.63M	30.95M	20.01M	22.98M	19.36M	49.65M
Total Debt	1.86M	22.94M	16.42M	30.43M	18.19M	30.97M
Total Liabilities	101.82M	105.21M	91.14M	98.48M	93.31M	128.10M
Stockholders Equity	23.17M	18.97M	27.72M	39.36M	44.31M	137.57M
Cash Flow
Free Cash Flow	-1.46M	-5.17M	-1.72M	-5.13M	-28.82M	-25.96M
Operating Cash Flow	-1.36M	-1.94M	-1.39M	-5.13M	-28.82M	-25.96M
Investing Cash Flow	-2.94M	-2.56M	-329.00K	-117.00K	-3.25M	-2.78M
Financing Cash Flow	16.83M	15.44M	-1.26M	8.87M	1.53M	30.31M

Aytu BioScience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Positive. The current price of 2.75 is above the 20-day moving average (MA) of 2.62, above the 50-day MA of 2.33, and above the 200-day MA of 2.07, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 59.59 is Neutral, neither overbought nor oversold. The STOCH value of 29.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AYTU.

Aytu BioScience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	53 Neutral	$24.77M	81.99	0.27%	―	75.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	49 Neutral	$28.02M	-0.90	-50.23%	―	-15.61%	-68.96%
FLGC	43 Neutral	$6.59M	-0.19	-37.38%	―	-22.60%	53.82%
COSM	40 Underperform	$16.69M	-0.63	-63.82%	―	―	―

Aytu BioScience Corporate Events

Aytu BioScience Stockholders Approve Key Proposals

On December 10, 2025, Aytu BioPharma, Inc. held its 2026 annual meeting of stockholders. During this meeting, stockholders voted on three key proposals. All incumbent directors standing for reelection were successfully elected by a majority vote. Additionally, the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, was ratified. Lastly, the stockholders approved the executive compensation proposal through a non-binding advisory vote.

The most recent analyst rating on (AYTU) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.